DNA polymerase lambda Antibodies

DNA polymerase lambda (POLL)

DNA polymerase that functions in several pathways of DNA repair (PubMed:11457865, PubMed:19806195, PubMed:20693240). Involved in base excision repair (BER) responsible for repair of lesions that give rise to abasic (AP) sites in DNA (PubMed:11457865, PubMed:19806195).

Also contributes to DNA double-strand fracture repair by non-homologous end joining and homologous recombination (PubMed:19806195, PubMed:20693240). Has both template-dependent and template-independent (terminal transferase) DNA polymerase activities (PubMed:10982892, PubMed:10887191, PubMed:12809503, PubMed:14627824, PubMed:15537631, PubMed:19806195).

Gene Information

Human
Gene Name:	POLL
Uniprot:	Q9UGP5
Entrez:	27343

Family

Belongs to:
DNA polymerase type-X family

Alternative Names

BETAN; DNA polymerase beta-2; DNA polymerase beta-N; DNA polymerase kappa; DNA polymerase lambda; EC 2.7.7.7; EC 4.2.99.-; FLJ46002; Pol beta2; Pol Lambda; POLKAPPA; polymerase (DNA directed), lambda

Molecular Weight

Mass (kDA):
63.482 kDA

Genomic Context

Human
Location:	10q24.32
Sequence:	10; NC_000010.11 (101578882..101588319, complement)

Tissue Specificity

Expressed in a number of tissues. Abundant in testis.

Subcellular Localizations

Nucleus.

Diseases

• Malignant Neoplasms
• Cattle Diseases
• Pain
• Acquired Immunodeficiency Syndrome
• Hiv Infections
• Neoplasms
• Mental Disorders
• Infective Disorder
• Depressive Disorder
• Hypertensive Disease
• Anxiety Disorders
• Obesity

• Substance-related Disorders
• Diabetes Mellitus
• Cardiovascular Diseases
• Flexed Fetal Attitude
• Sleep Disorders
• Stress, Psychological
• Edema

Interacting Proteins

• FAM9B
• FSD2
• KRT40
• KRTAP10-7
• MAGEA12

• PNMA1
• SSX2IP
• TFCP2
• TFIP11
• TRIM23

Pathways

• Mating
• Lactation
• Parturition
• Aging
• Pathogenesis
• Transport
• Secretion
• Ovulation
• Translation
• Estrus
• Menopause
• Reflex
• Dna Repair

• Insemination
• Reproductive Behavior
• Fertilization
• Virulence
• Localization
• Social Behavior
• Cell Adhesion

PTMs

• Phosphorylation
• Phosphorothioation

• Oxidation
• Methylation

Research Areas

• Adaptive Immunity
• Immunology

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/POLL

Best Uses Of The POLL Marker

Steven Boster, a Chinese biotechnology businessman, is the creator of the POLL marker. Boster created his first product in 1993. He earned the nickname "he who converted science in the lavatory" Since then, Boster has developed a wide range of immunoassay products that include hundreds of primary antibodies. Boster Bio became the largest catalog antibody manufacturer in China in the end of the 90s. PicoKine(tm) is a proprietary ELISA platform that Boster Bio has created. These kits are suitable for sensitive assays , and offer high-sensitivity ELISA capabilities.

InVivo Biosystems Custom zebrafish/c. elegans genome edited models for DNTT

InVivo Biosystems provides custom genome-edited zebrafish/c. elegans models to assist in development, discovery and commercialization. The company offers the genetic engineering tools needed to build these models as well as in-vivo analytic services. Models that are customized can be derived from any one of the many species, including worms, rats, mice, human, and yeast.

The genome-editing tool that is comprehensive for the c. Zerbfish and elegans genotyping is fast and precise, allowing researchers the ability to extract gDNA in a shorter time than traditional methods. The kit can create high-quality gDNA templates within one embryolysis reaction, which minimizes sample loss and eliminates the need for multiple washing steps for the sample. Furthermore, gDNA can be directly used in PCR reactions to facilitate the analysis of a wide variety of genes.

InVivo Biosystems Custom zebreafish/c. Models that are edited by elegans can be used to test new therapies. Custom models can be constructed by integrating reporter genes heterologous nucleic acid or transgenic technology to modify the expression of genes in various cell kinds.

DNTT hybridizations have to be conducted using DNA-containing filter. The DNA is then processed using the solution which contains 35 percent formamide, 5xSSC as well as 5mM of EDTA , for six hours. The filter is then incubated in the mixture of hybridization for 18 to 20 hours at a temperature of 55 degrees C. The filters are then blotted dry and exposed to autoradiography.

InVivo Biosystems custom zebrafish/c. To investigate the effects of DNTT on genes that regulate stress and quorum sensing you can use models that genome-edit elegans to study DNTT. Custom zebrafish/c. elegans genome-editing models for DNTT will be tailored to your requirements.

Genes encode RNA and proteins from heterologous nucleic acid, and their expression in cells indicates an entirely new role for this gene in neurodegenerative disorders. For instance the role of gene therapy could be more understood if genes responsible for the disease can be identified through DNTT. If this is the case InVivo Biosystems Custom-zebrafish/c. elegans genome edited models will aid in testing the efficacy of new drugs.

PharmaAntitumor Agent that forms platinum-based DNA adducts

It has been demonstrated in detail how cisplatin, a drug that is used to treat cancer, is effective. The platinum drug is believed that it forms DNA adducts within cancerous cells, preventing the cell from carrying out normal cell processes and , consequently, causing cell death. However, this drug has its own set of issues, including its potential to cause resistance to the chemotherapy agent. But, there are other platinum-based compounds that have been developed to be used as antitumour medications.

A platinum-DNA adduct can be an inhibitor of transcription. Platinum-modified DNA is able to attract transcription factors to the area of damage and prevent them from binding to the promoter. It also blocks the formation of transcriptional complexes by creating physical blocks for RNA polymerases. Platinum-DNA adducts may also alter nucleosomal structure and mobility. They also block transcription by blocking access to DNA.

The main differences between platinum (II) and platinum(IV) analogs are the amount of ligands that are used and the formal charge of the platinum center. The one binds to DNA in similar sites as its platinum(II) counterpart. The latter binds DNA at a similar location and allows it to block transcription by DNA-dependentRNA polymerase.

This anticancer drug blocks transcription in cancer cells by creating platinum DNA adducts. It blocks cell-mediated responses by making bifunctional platinum adducts. Platinum-DNA adducts inhibit transcription by preventing RNA synthesis. A increased risk of developing cancer is associated with the inhibition of transcription by platinum DNA adducts.

Another drug that creates platinum DNA adducts, cisplatin. This antitumor agent based on platinum has a wide spectrum of anti-tumor activity and is extremely effective against cancer cells. It has a sophisticated molecular mechanism of action. These compounds are known to stop the growth and death of cancer cells in four different stages. This goal is currently being explored by more than 60 researchers.